2026-04-29T20:38:14Zhttps://riubu.ubu.es/oai/request

oai:riubu.ubu.es:10259/52432024-05-15T10:40:08Zcom_10259_4725com_10259_5086com_10259_2604col_10259_4726

00925njm 22002777a 4500 dc González López, Tomás José author Sánchez González, Blanca author Jarque, Isidro author Bernat, Silvia author Fernández Fuertes, Fernando author Caparrós, Isabel author Soto, Inmaculada author Fernández Rodríguez, Angeles author Bolaños, Estefanía author Pérez Rus, Gloria author Pascual, Cristina author Hernández Rivas, José Angel author López Ansoar, Elsa author Gómez Nuñez, Marta author Martínez Robles, Violeta author Olivera, Pavel author Yera Cobo, Maria author Peñarrubia, María Jesús author Fernández Miñano, Carmen author Cabo, Erik author Martínez Badas, María Paz author Perdomo Hernández, Germán M. author García Frade, Luis Javier author 2020-03 Background Eltrombopag is useful for immune thrombocytopenia (ITP). However, results of clinical trials may not accurately mirror clinical practice reality. Here we evaluated eltrombopag for primary and secondary ITP in our ≥65‐year‐old population. Methods A total of 106 primary ITP patients (16 with newly diagnosed ITP, 16 with persistent ITP, and 74 with chronic ITP) and 39 secondary ITP patients (20 with ITP secondary to immune disorders, 7 with ITP secondary to infectious diseases, and 12 with ITP secondary to lymphoproliferative disorders [LPD]) were retrospectively evaluated. Results Median age of our cohort was 76 (interquartile range, IQR, 70‐81) years. 75.9% of patients yielded a platelet response including 66.2% complete responders. Median time to platelet response was 14 (IQR, 8‐21) days. Median time on response was 320 (IQR, 147‐526) days. Sixty‐three adverse events (AEs), mainly grade 1‐2, occurred. The most common were hepatobiliary laboratory abnormalities (HBLAs) and headaches. One transient ischemic attack in a newly diagnosed ITP and two self‐limited pulmonary embolisms in secondary ITP were the only thrombotic events observed. Conclusion Eltrombopag showed efficacy and safety in ITP patients aged ≥65 years with primary and secondary ITP. However, efficacy results in LPD‐ITP were poor. A relatively high number of deaths were observed. 0902-4441 http://hdl.handle.net/10259/5243 10.1111/ejh.13370 1600-0609 Elderly Eltrombopag Immune thrombocytopenia Primary Secondary Use of eltrombopag for patients 65 years old or older with immune thrombocytopenia